Therma Bright Inc : Therma Bright Reports Performance of Its AcuVid COVID-19 Rapid Antigen Saliva Test from Brazilian Clinical Study finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Toronto, Ontario–(Newsfile Corp. – May 27, 2021) –
Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to provide the following update on its Brazilian clinical study of its innovative 15- minute COVID-19 antigen saliva test.
We apologize, but this video has failed to load.
Try refreshing your browser. Therma Bright Provides Update on Brazilian Clinical Study Back to video
Following last week’s announcement on securing K-One MediTech as the Asia-based manufacturer, the Company has finalized the AcuVid™ test kit specifications and is initiating the clinical evaluation study of this simple, easy-to-use and cost-effective kit, and anticipates a full update on the progress from its Brazilian partners at Federal University of Minas Gerais within the next 8 to 12 days.
Brazilian Health Regulatory Agency (ANVISA) Authorizes globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.